RIT2

Across TCGA pan-cancer cohorts, RIT2 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated RIT2 data layer compared with 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RIT2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RIT2 expression acts as an unfavorable survival marker, although some lineages such as READ and KIRC show a favorable association.

LUAD, STAD, and READ are the cancer types where RIT2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	IV	0.375	0.763	.012	54	view →
STAD	DFS	Median	All	0.561	0.780	.001	39	view →
READ	DFS	Tertile	All	0.891	0.650	.011	33	view →
THCA	DFS	Tertile	III,IV	0.697	0.899	.005	24	view →
KIRC	OS	Median	All	0.904	0.850	.008	23	view →
ESCA	OS	Tertile	All	0.471	0.906	.031	18	view →
OV	DFS	Quartile	IV	0.280	0.502	.008	14	view →
PRAD	DFS	Quartile	All	0.757	0.904	.008	12	view →
TGCT	DFS	Tertile	All	0.616	0.798	.021	10	view →
ACC	DFS	Tertile	IV	0.779	0.252	.021	9	view →
SCLC	DFS	Median	II,III,IV	0.706	0.392	.014	8	view →
COAD	OS	Tertile	All	0.850	0.591	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

RIT2–LUAD (DFS)

Open the LUAD breakdown →